Trials / Completed
CompletedNCT02708576
Phase 1 Study of NGM313 in Healthy Adult Participants
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM313 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2016-03-15
- Last updated
- 2017-09-14
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT02708576. Inclusion in this directory is not an endorsement.